Endocrine Abstracts

Introduction: Adrenocortical tumors (ACTs) are usually divided in adenoma (ACA) or carcinoma (ACC) according to histopathologic methods. Some lesions are occasionally difficult to classify according to these criteria. We studied the use of some immunohistochemical markers to recognise the difference between malignant and benign tumors.Materials and methods: We studied 12 patients affected by ACC and 10 by ACA. Clinical evaluation and hormone analysis wer...

Background: Deciding whether patients with a cytologically indeterminate thyroid nodule should be referred for surgery or for active surveillance is an important challenge for clinicians. The aim of this study was to evaluate the performance of a novel dual-component molecular assay as an ancillary molecular method for resolving indeterminate thyroid nodule cytology.Methods: We selected 156 thyroid nodules from those that had undergone both FNA cytology ...

Background: Differentiated Thyroid Carcinomas (DTC) represent more than 90% of thyroid tumors with good prognosis and long survival. Currently, patients with intermediate/high risk nodule as assessed by cytological staging may undergo surgery. According to ATA 2017 guidelines, all patients presenting thyroid nodules with suspicious ultrasound features (hypoechoic pattern, irregular margins, microcalcifications, etc.) and cytopathology TIR3B, TIR4 or TIR5 according to 2014-SIAP...

Introduction: Adrenocortical tumours comprise frequent adenomas (ACA) and rare highly malignant carcinoma (ACC). Livin/ML-IAP/BIRC7 is a member of the inhibitors of apoptosis proteins family, which are involved in tumorigenesis, mostly through the inhibition of caspase-3. Aim of the study was to evaluate the expression of livin/BIRC7 in normal and neoplastic adrenal glands.Methods: The mRNA expression of BIRC7, its isoforms livin α...

Radioiodide 131I (RAI) is the therapy of choice for radioiodine-avid differentiated thyroid cancer (DTC). However, 5–15% of DTC patients become RAI refractory (RAIR), and the 10-year survival rate for metastatic disease decreases to 10%. The failure of RAI response is mainly due to the loss of thyroid differentiation, that leads to the loss of expression/function of components of iodide metabolism, first of all the Na/I symporter (NIS). The finding that the MAPK pathway i...